Pharma channel feed

Mike Bloomberg joins a grow­ing cho­rus of De­mo­c­ra­t­ic pres­i­den­tial can­di­dates threat­en­ing to go af­ter drug patents

6 years ago
People

J&J's Spra­va­to gets no love from NICE, jeop­ar­diz­ing its prospects in the UK

6 years ago

Breast can­cer ap­proval in tow, As­traZeneca, Dai­ichi armed an­ti­body scores in key gas­tric can­cer study

6 years ago
R&D

As­traZeneca makes case for use of blood thin­ner Bril­in­ta in stroke pa­tients

6 years ago
R&D

Gilead claims Tru­va­da patents in HHS’ com­plaint are in­valid

6 years ago

Tri­fec­ta of sick­le cell dis­ease ther­a­pies ex­tend life ex­pectan­cy, but are not cost-ef­fec­tive — ICER

6 years ago

Drug-drug in­ter­ac­tions: FDA is­sues guid­ance on clin­i­cal, in vit­ro stud­ies

6 years ago
FDA+

FDA waves Epizyme's $186K rare can­cer drug through to mar­ket — now get ready for the sec­ond act

6 years ago
FDA+

2019 a 'trans­for­ma­tive year' for phar­ma M&A. Is that a good thing?

6 years ago
Deals

Roche cracks Chi­na's ADC mar­ket open as Kad­cy­la scores its first breast can­cer OK in the coun­try

6 years ago
China

Wuhan virus out­break trig­gers in­evitable small-biotech ral­ly

6 years ago
Coronavirus

Eli Lil­ly re­serves $470M for new man­u­fac­tur­ing plant — and North Car­oli­na is more than pleased

6 years ago

FDA hands off its lat­est whirl­wind drug OK as Hori­zon hus­tles would-be block­buster to the mar­ket

6 years ago
FDA+

As­traZeneca plans to spend $535M-plus to ex­pand its R&D net­work and man­u­fac­tur­ing ops in France

6 years ago

Bernie Sanders goes af­ter Bio­Mar­in's shot at a record drug price, threat­en­ing to break the patent

6 years ago
People
Bioregnum

GSK, Pfiz­er con­tra­dict on the fu­ture of con­sumer health JV — re­port

6 years ago

War­ren and Klobuchar say they can low­er drug prices with­out Con­gress’ help

6 years ago
People

Ab­b­Vie's Skyrizi hangs No­var­tis' Cosen­tyx out to dry in head-to-head pso­ri­a­sis study

6 years ago

#JPM20: 'The NPV is al­ways wrong.' Take­da preps an­oth­er spin­out — this time on psych

6 years ago
R&D

Roche aims to 'un­der­whelm' with ris­diplam price as it en­ters SMA ri­val­ry with Bio­gen, No­var­tis — re­port

6 years ago

Amar­in's Vas­cepa reigns supreme in fish oil bat­tle, as As­traZeneca's ri­val fiz­zles

6 years ago
R&D

Alex­is Borisy has $200M to back a mar­ket-based plan aimed at cur­ing Amer­i­ca’s drug pric­ing ‘sick­ness’

6 years ago
Financing

J&J plans to re­cruit a new gen­er­a­tion of 'bilin­gual' sci­en­tists for a re­search fa­cil­i­ty blue­print­ed for the boom­ing Bay Area

6 years ago

Blue­print scores first FDA OK for a pre­ci­sion GIST can­cer drug, just ahead of a ri­val treat­ment. And the price is a big sur­prise

6 years ago
FDA+
First page Previous page 257258259260261262263 Next page Last page
A service from the Financial Times